stock decline

Kessler Topaz files securities fraud suit against $GEMI after 78.7% stock collapse following February 2026 corporate pivot, layoffs, market exits.

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.

Navan faces securities lawsuit over allegedly omitted $95M sales expense surge in IPO documents; stock down 63% from $25 offering price.

Tenable stock plunged 8.5% after Anthropic revealed Claude Mythos AI model can exploit cybersecurity vulnerabilities faster than defenders can respond.

Sony raises PS5 prices $100-$150 globally starting April 2026 amid memory cost inflation and AI chip demand pressures; stock down 21.88% yearly.

Palo Alto Networks stock dropped 7% amid reports of Anthropic's advanced Claude Mythos AI model with cybersecurity capabilities, raising competitive concerns.

Disc Medicine faces securities probe after FDA rejects bitopertin drug; stock slides 22% on February 13, 2026.

Rapid7 acquired Kenzo Security to add AI-driven autonomous security operations to its Command Platform, but shares fell 2.28% premarket on Friday amid broader stock weakness.

Chipotle faces 53% stock decline from June 2024 peak amid weak sales, but aggressive expansion plans targeting 7,000 North American stores offer contrarian investors potential recovery opportunity.

Class action lawsuit filed against ImmunityBio for allegedly making false statements about cancer treatment Anktiva. FDA issued warning letter; stock fell 21% after disclosure.

FICO stock declines as competitive pressures erode its traditional market dominance and pricing power, raising questions about whether the dip offers opportunity or reflects fundamental business deterioration.

PayPal faces securities fraud lawsuit over false growth claims. Stock dropped 20.3% after surprise CEO change and missed earnings. Investors have until April 20, 2026, for lead plaintiff status.

$MU reports stellar Q2 results with 196% revenue growth, but analysts warn stock faces 30-50% downside risk if memory cycle turns despite cheap 8x forward P/E valuation.

ADMA Biologics faces securities fraud investigation for alleged channel stuffing, resulting in 29.1% stock decline to $9.63 per share.

Securities fraud investigation launched into $GEMI following 79% stock collapse from $28 IPO price to $5.96 after February 2026 strategic pivot announcement.

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly failing to disclose FDA deficiencies in Anaphylm NDA, causing 37% stock decline.

Portnoy Law Firm sues Alight for allegedly misrepresenting revenue and growth projections. Stock plummeted 18% in August 2025 and 38% in February 2026.

Trip.com faces class action suit alleging antitrust disclosure failures. Stock plunged 19% after Chinese regulators' investigation revealed.

Portnoy Law Firm sues Soleno Therapeutics for allegedly concealing DCCR safety risks in Phase 3 trials, citing 27% stock drop on November 4, 2025.

Micron's 771% earnings surge failed to lift stock price, revealing investor skepticism about cyclical chip market recovery despite exceptional quarterly results.